Drug Profile
Danirixin - GSK
Alternative Names: 1325756; DNX; GSK-1325756; GSK-1325756H; GSK1325756BLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Anti-inflammatories; Antivirals; Piperidines; Small molecules; Sulfones
- Mechanism of Action Interleukin 8B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Influenza virus infections
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Influenza-virus-infections in United Kingdom (IV, Infusion)
- 15 May 2020 Efficacy and adverse events data from a phase II trial in Chronic obstructive pulmonary disease presented at the 116th International Conference of the American Thoracic Society (ATS-2020)
- 24 Jan 2019 GlaxoSmithKline terminates a phase II trial in Chronic Obstructive Pulmonary Disease in United kingdom(NCT03250689)